Aaron Wolfson, MD
Advanced Heart Failure and Transplant Cardiology · Los Angeles, CANPI 1144584913
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,441 of the $15,672 with a category attached, or 79.4%. Edwards Lifesciences accounts for 79.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $8,590 and has fallen 95.1% since, to $423 in 2025.
Across 63 payments — averaging $248.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$12K
- Abbott$1K
- Abiomed$1K
- Impulse Dynamics (USA) Inc.$222
- W. L. Gore & Associates, Inc.$118
- Medtronic$106
- plus $352 from 9 others
Across 8 payments — averaging $10,640 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$50K
- Amgen$18K
- Endotronix, Inc.$15K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$12,44179%
- Food & beverage$3,15120%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 11 | $12,441 |
| Abbott | 26 | $1,330 |
| Abiomed | 10 | $1,103 |
| Impulse Dynamics (USA) Inc. | 3 | $222 |
| W. L. Gore & Associates, Inc. | 1 | $118 |
| Medtronic | 1 | $106 |
| Astellas Pharma US Inc | 1 | $80 |
| Irhythm Technologies, Inc. | 1 | $51 |
| Ancora Heart, Inc. | 2 | $51 |
| Baxter Healthcare | 2 | $46 |
| Scpharmaceuticals Inc. | 1 | $35 |
| Cvrx, Inc. | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Cook Medical LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,672 in reported general payments places this provider in the 55th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndaqelTafamidis Meglumine | 11 | $284,956 |
| CamzyosMavacamten | 12 | $104,637 |
| EntrestoSacubitril/Valsartan | 13 | $24,066 |
| JardianceEmpagliflozin | 18 | $21,088 |
| EliquisApixaban | 17 | $20,604 |
| Spironolactone | 38 | $508 |
| Metoprolol Succinate | 32 | $401 |
| Carvedilol | 18 | $366 |
| Atorvastatin Calcium | 12 | $159 |
| Furosemide | 12 | $100 |
| Losartan Potassium | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Los Angeles
- Eugene DepasqualeLos Angeles$104K
- Joseph RahmanLos Angeles$101K
- Jon KobashigawaLos Angeles$54K
- Ajay VaidyaLos Angeles$17K
- Michael FongLos Angeles$9K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.